{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T04:05:50Z","timestamp":1743134750440,"version":"3.40.3"},"reference-count":25,"publisher":"BMJ","issue":"2","funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2023,11,28]]},"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1136\/ejhpharm-2023-003937","type":"journal-article","created":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T18:20:13Z","timestamp":1702146013000},"page":"166-171","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Inhaled aztreonam lysine in the management of<i>Pseudomonas aeruginosa<\/i>in patients with cystic fibrosis: real-life effectiveness"],"prefix":"10.1136","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4473-6768","authenticated-orcid":false,"given":"In\u00e9s","family":"Jim\u00e9nez-Lozano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Luna-Paredes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Monte-Boquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurora","family":"Fern\u00e1ndez-Polo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carme","family":"Ca\u00f1ete-Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Roch-Santed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Gartner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"\u00c1lvarez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,12,9]]},"reference":[{"key":"2025032704500678000_32.2.166.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12567-6"},{"key":"2025032704500678000_32.2.166.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32542-3"},{"key":"2025032704500678000_32.2.166.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-1993(02)00141-8"},{"key":"2025032704500678000_32.2.166.4","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201404-166OC"},{"key":"2025032704500678000_32.2.166.5","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics10030338","article-title":"Cystic fibrosis: recent insights into inhaled antibiotic treatment and future perspectives","volume":"10","author":"Taccetti","year":"2021","journal-title":"Antibiotics"},{"key":"2025032704500678000_32.2.166.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2009.04.005"},{"key":"2025032704500678000_32.2.166.7","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/ppul.25942","article-title":"Use of inhaled antibiotics among Danish patients with cystic fibrosis","volume":"57","author":"M\u00f8ller","year":"2022","journal-title":"Pediatr Pulmonol"},{"key":"2025032704500678000_32.2.166.8","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200712-1804OC"},{"key":"2025032704500678000_32.2.166.9","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-1421"},{"key":"2025032704500678000_32.2.166.10","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.21301"},{"key":"2025032704500678000_32.2.166.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2012.07.006"},{"key":"2025032704500678000_32.2.166.12","unstructured":"European Medicines Agency . Cayston: product information and assessment report. 2009. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cayston [Accessed 12 Dec 2022]."},{"key":"2025032704500678000_32.2.166.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2018.02.006"},{"key":"2025032704500678000_32.2.166.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199409083311003"},{"key":"2025032704500678000_32.2.166.15","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.20873"},{"key":"2025032704500678000_32.2.166.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2008.09.024"},{"key":"2025032704500678000_32.2.166.17","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2011.161117"},{"key":"2025032704500678000_32.2.166.18","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00166412"},{"key":"2025032704500678000_32.2.166.19","doi-asserted-by":"publisher","DOI":"10.1378\/chest.121.1.64"},{"key":"2025032704500678000_32.2.166.20","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00057-2017","article-title":"Weight gain during acute treatment of an initial pulmonary exacerbation is associated with a longer interval to the next exacerbation in adults with cystic fibrosis","volume":"3","author":"Barr","year":"2017","journal-title":"ERJ Open Res"},{"key":"2025032704500678000_32.2.166.21","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.endonu.2015.06.009","article-title":"Association between relative weight change and body mass index with lung function in adolescents and adults with cystic fibrosis: influence of gender and diabetes","volume":"62","author":"Cano Meg\u00edas","year":"2015","journal-title":"Endocrinolog\u00eda y Nutrici\u00f3n"},{"key":"2025032704500678000_32.2.166.22","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.57.7.596"},{"key":"2025032704500678000_32.2.166.23","first-page":"4","article-title":"Nutritional management of cystic fibrosis - an update for the 21st century","volume":"26","author":"Collins","year":"2018","journal-title":"Paediatr Respir Rev"},{"key":"2025032704500678000_32.2.166.24","article-title":"Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis","volume":"4","author":"Langton Hewer","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2025032704500678000_32.2.166.25","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.jcf.2017.02.006","article-title":"A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis","volume":"16","author":"Plant","year":"2017","journal-title":"J Cyst Fibros"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2023-003937","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T12:03:08Z","timestamp":1743076988000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2023-003937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,9]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,21]]},"published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1136\/ejhpharm-2023-003937"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2023-003937","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"type":"print","value":"2047-9956"},{"type":"electronic","value":"2047-9964"}],"subject":[],"published":{"date-parts":[[2023,12,9]]}}}